Sareum HoldingsFRA:RYH0 36 Return-on-Tangible-Equity is -186.84% as of Dec. 2025. GuruFocus rates FRA:RYH0 with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 1,199 Biotechnology companies, Sareum Holdings ranks worse than 85.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sareum Holdings's annualized net income for the quarter that ended in Dec. 2025 was €-3.78 Mil. Sareum Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €2.02 Mil. Therefore, Sareum Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -186.84%.
The historical rank and industry rank for Sareum Holdings's Return-on-Tangible-Equity or its related term are showing as below:
FRA:RYH0'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -209.37 Med: -70.97 Max: 19
Current: -189.55
During the past 13 years, Sareum Holdings's highest Return-on-Tangible-Equity was 19.00%. The lowest was -209.37%. And the median was -70.97%.
FRA:RYH0's Return-on-Tangible-Equity is ranked worse than 85.4% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs FRA:RYH0: -189.55
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sareum Holdings Return-on-Tangible-Equity Related Terms
Sareum Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sareum Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RYH0 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sareum Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sareum Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sareum Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sareum Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -186.84% mean?
Sareum Holdings (FRA:RYH0) has a Return-on-Tangible-Equity of -186.84% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sareum Holdings and its competitors. According to the industry distribution chart, Sareum Holdings ranks #1024 out of 1199 companies in the Biotechnology industry, placing it in the top 85.4%.
Is Sareum Holdings' Return-on-Tangible-Equity too high?
Sareum Holdings' current Return-on-Tangible-Equity is -186.84%. Based on the distribution chart, Sareum Holdings ranks #1024 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sareum Holdings has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Sareum Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sareum Holdings ranks #1024 out of 1199 companies for Return-on-Tangible-Equity. This places Sareum Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sareum Holdings and its competitors. Sareum Holdings's current Return-on-Tangible-Equity is -186.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sareum Holdings stock overvalued right now?
Sareum Holdings (FRA:RYH0) has a current Return-on-Tangible-Equity of -186.84%. The current Return-on-Tangible-Equity is -186.84%. Sareum Holdings' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sareum Holdings (FRA:RYH0), the current Return-on-Tangible-Equity is -186.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
36GF Score
Get the complete analysis for FRA:RYH0
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RYH0 has been successfully added to your 
